MX341119B - Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail). - Google Patents
Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail).Info
- Publication number
- MX341119B MX341119B MX2012011840A MX2012011840A MX341119B MX 341119 B MX341119 B MX 341119B MX 2012011840 A MX2012011840 A MX 2012011840A MX 2012011840 A MX2012011840 A MX 2012011840A MX 341119 B MX341119 B MX 341119B
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- trail
- loop comprises
- loop
- monomeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32370810P | 2010-04-13 | 2010-04-13 | |
| PCT/US2011/032188 WO2011130328A1 (en) | 2010-04-13 | 2011-04-12 | Trail r2-specific multimeric scaffolds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012011840A MX2012011840A (es) | 2012-12-17 |
| MX341119B true MX341119B (es) | 2016-08-09 |
Family
ID=44799000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012011840A MX341119B (es) | 2010-04-13 | 2011-04-12 | Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail). |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130079280A1 (https=) |
| EP (2) | EP2560684A4 (https=) |
| JP (2) | JP6041799B2 (https=) |
| KR (2) | KR101747991B1 (https=) |
| CN (2) | CN102834114A (https=) |
| AU (2) | AU2011240620A1 (https=) |
| BR (1) | BR112012026003B1 (https=) |
| CA (2) | CA2795325A1 (https=) |
| ES (1) | ES2755398T3 (https=) |
| MX (1) | MX341119B (https=) |
| RU (1) | RU2628699C2 (https=) |
| SG (2) | SG184185A1 (https=) |
| WO (2) | WO2011130328A1 (https=) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
| CA2670471A1 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| CN102007145A (zh) | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| CA2795325A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| ES2573108T3 (es) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada |
| RS55609B1 (sr) | 2011-04-13 | 2017-06-30 | Bristol Myers Squibb Co | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane |
| EP3318880B1 (en) | 2011-05-17 | 2020-12-16 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| AU2012323316B2 (en) | 2011-10-11 | 2017-08-10 | Viela Bio, Inc. | CD40L-specific Tn3-derived scaffolds and methods of use thereof |
| EP2773659A2 (en) | 2011-10-31 | 2014-09-10 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
| CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| CN104136457A (zh) | 2011-11-08 | 2014-11-05 | Umc乌德勒支控股有限公司 | 包括白细胞介素10和白细胞介素4的融合蛋白 |
| TWI633117B (zh) | 2012-09-13 | 2018-08-21 | 必治妥美雅史谷比公司 | 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質 |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| EP2951206A2 (en) | 2013-02-01 | 2015-12-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| ES2689372T3 (es) | 2013-02-06 | 2018-11-13 | Bristol-Myers Squibb Company | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
| ES2870802T3 (es) | 2013-02-12 | 2021-10-27 | Bristol Myers Squibb Co | Métodos de replegado de proteínas a elevado pH |
| EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| US20160152686A1 (en) | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
| ES2812208T3 (es) | 2013-03-14 | 2021-03-16 | Bristol Myers Squibb Co | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso |
| US10392611B2 (en) | 2013-05-30 | 2019-08-27 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| US10364451B2 (en) | 2013-05-30 | 2019-07-30 | Duke University | Polymer conjugates having reduced antigenicity and methods of using the same |
| CN105899226B (zh) | 2013-10-14 | 2020-05-12 | 詹森生物科技公司 | 半胱氨酸工程化iii型纤连蛋白域结合分子 |
| US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
| CN106795214B (zh) | 2014-03-20 | 2022-09-02 | 百时美施贵宝公司 | 稳定化的基于纤连蛋白的支架分子 |
| EP3129401B1 (en) | 2014-03-20 | 2019-06-12 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
| WO2015148269A2 (en) * | 2014-03-24 | 2015-10-01 | Medimmune, Llc | Stabilized tnfn3 scaffold proteins |
| NO2776305T3 (https=) | 2014-04-23 | 2018-01-27 | ||
| US10562946B2 (en) * | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
| JP6863888B2 (ja) | 2014-10-01 | 2021-04-21 | メディミューン，エルエルシー | ポリペプチドをコンジュゲートさせる方法 |
| MX385081B (es) | 2014-11-25 | 2025-03-14 | Bristol Myers Squibb Co | Métodos y composiciones para radioetiquetado con 18f de productos biológicos. |
| EP3842451A1 (en) | 2015-03-12 | 2021-06-30 | MedImmune, LLC | Method of purifying albumin-fusion proteins |
| US10385115B2 (en) | 2015-03-26 | 2019-08-20 | Duke University | Fibronectin type III domain-based fusion proteins |
| US10844122B2 (en) * | 2015-05-06 | 2020-11-24 | Janssen Biotech, Inc. | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof |
| JP6882782B2 (ja) | 2015-08-04 | 2021-06-02 | デューク ユニバーシティ | 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法 |
| WO2017048709A1 (en) | 2015-09-14 | 2017-03-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Generating recominant affinity reagents with arrayed targets |
| EP3708580B1 (en) | 2015-09-23 | 2023-11-01 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| ES2809125T3 (es) | 2015-09-23 | 2021-03-03 | Bristol Myers Squibb Co | Moléculas de armazón a base de fibronectina de unión a glipicano-3 |
| JP7174627B2 (ja) * | 2015-10-23 | 2022-11-17 | ウニフェルシタイト・トゥヴェンテ | インテグリン結合ペプチド及びその使用 |
| WO2017106627A1 (en) | 2015-12-17 | 2017-06-22 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| KR102508650B1 (ko) | 2016-04-07 | 2023-03-13 | 더 존스 홉킨스 유니버시티 | 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법 |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| CN105802970A (zh) * | 2016-05-30 | 2016-07-27 | 东北师范大学 | 靶向沉默Gβ1的shRNA |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
| JP2019527540A (ja) | 2016-06-21 | 2019-10-03 | ヤンセン バイオテツク，インコーポレーテツド | システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子 |
| RU2019110848A (ru) | 2016-09-14 | 2020-10-15 | Дьюк Юниверсити | Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств |
| EP3515928B1 (en) | 2016-09-23 | 2026-01-28 | Duke University | Unstructured non-repetitive polypeptides having lcst behavior |
| US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
| NZ754187A (en) | 2016-12-14 | 2026-02-27 | Janssen Biotech Inc | Cd8a-binding fibronectin type iii domains |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| US10787499B2 (en) * | 2017-02-13 | 2020-09-29 | Regents Of The University Of Minnesota | EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof |
| WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
| US12296018B2 (en) | 2018-01-26 | 2025-05-13 | Duke University | Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same |
| US11491206B1 (en) | 2018-02-13 | 2022-11-08 | Duke University | Compositions and methods for the treatment of trail-resistant cancer |
| US11680091B2 (en) | 2018-02-23 | 2023-06-20 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type III (FN3) monobodies |
| EP3788343B1 (en) | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
| EP3829622A4 (en) | 2018-08-02 | 2022-05-11 | Duke University | DOUBLE AGONIST FUSION PROTEINS |
| WO2020051541A1 (en) | 2018-09-07 | 2020-03-12 | Duke University | Nanoparticulate drug delivery systems |
| EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| EP3999091A1 (en) | 2019-07-15 | 2022-05-25 | MedImmune Limited | Tripartite systems for protein dimerization and methods of use |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| CN111217903B (zh) * | 2020-02-25 | 2022-11-15 | 芜湖天明生物技术有限公司 | 一种重组人纤连蛋白ⅲ1-c及其制备方法和应用 |
| JP2023515633A (ja) | 2020-02-28 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用 |
| CN116249549A (zh) | 2020-03-27 | 2023-06-09 | 诺华股份有限公司 | 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法 |
| US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
| CN111944204B (zh) * | 2020-07-24 | 2022-03-08 | 南京理工大学 | 一种Fe3O4磁性细菌纤维素及其制备方法 |
| EP4216990A1 (en) | 2020-09-23 | 2023-08-02 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| IL301332A (en) | 2020-09-23 | 2023-05-01 | Ablevia Biotech Gmbh | Compound for the prevention or treatment of autoantibody-mediated conditions |
| CA3192753A1 (en) | 2020-09-23 | 2022-03-31 | Oskar SMRZKA | Compound for increasing the efficacy of factor viii replacement therapy |
| BR112023005246A2 (pt) | 2020-09-23 | 2023-04-25 | Ablevia Biotech Gmbh | Composto para o sequestro de anticorpos anti-peg indesejáveis em um paciente |
| JP2023542390A (ja) | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | ウイルスベクターの有効性を増強するための化合物 |
| EP4217401A1 (en) | 2020-09-24 | 2023-08-02 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| US20250215081A1 (en) | 2020-11-06 | 2025-07-03 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| AU2023238299A1 (en) | 2022-03-24 | 2024-11-07 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
| KR102459313B1 (ko) * | 2022-04-11 | 2022-10-26 | 주식회사 대영방재산업 | 내구성이 개선된 소방용 수격 흡수기 |
| CN121752717A (zh) | 2023-06-23 | 2026-03-27 | 阿斯利康(瑞典)有限公司 | 分子开关 |
| WO2025125630A1 (en) | 2023-12-15 | 2025-06-19 | Medimmune Limited | Method for bioprotac design |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482410B1 (en) | 1994-09-16 | 2002-11-19 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6160089A (en) | 1998-07-08 | 2000-12-12 | Mitsui Chemicals, Inc. | Method for secretory production of human growth hormone |
| BR9913435A (pt) * | 1998-08-28 | 2001-09-25 | Genentech Inc | Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DE69941267D1 (de) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | Proteingerüste für antikörper-nachahmer und andere bindende proteine |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK1495128T3 (da) | 2002-03-29 | 2014-08-11 | Genencor Int | Forstærket proteinekspression i Bacillus |
| WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
| CA2489348A1 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
| CN1946417A (zh) | 2003-12-05 | 2007-04-11 | 阿德内克休斯治疗公司 | 2型血管内皮生长因子受体的抑制剂 |
| WO2005056605A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | ３量体以上の受容体を認識する改変抗体 |
| GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
| UA97096C2 (ru) * | 2005-08-31 | 2012-01-10 | Емджен Інк. | Выделенное антитело, которое специфически связывает рецептор-2 trail (tr-2) |
| US10183986B2 (en) * | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| CN101371124B (zh) | 2006-02-13 | 2012-02-29 | 新加坡科技研究局 | 处理生物样品和/或化学样品的方法 |
| CN101074261A (zh) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | Trail受体1和/或trail受体2特异性抗体及其应用 |
| WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
| CA2670471A1 (en) | 2006-11-22 | 2008-06-05 | Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir |
| US20090176654A1 (en) | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2215246B1 (en) * | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Protein scaffolds |
| JP2011507543A (ja) | 2007-12-27 | 2011-03-10 | ノバルティス アーゲー | 改善されたフィブロネクチンベースの結合分子およびそれらの使用 |
| PL2274331T3 (pl) | 2008-05-02 | 2014-04-30 | Novartis Ag | Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie |
| PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
| CA2739663A1 (en) * | 2008-10-10 | 2010-05-15 | Anaphore, Inc. | Polypeptides that bind trail-r1 and trail-r2 |
| BRPI0919881B1 (pt) | 2008-10-31 | 2021-09-08 | Centocor Ortho Biotech Inc | Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| BRPI1008532B1 (pt) | 2009-02-12 | 2021-12-14 | Janssen Biotech, Inc | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
| EP2464663A4 (en) | 2009-08-13 | 2013-05-29 | Massachusetts Inst Technology | MANIPULATED PROTEINS WITH MUTANT FIBRONECTIN DOMAINS |
| CA2795325A1 (en) * | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
-
2011
- 2011-04-12 CA CA2795325A patent/CA2795325A1/en not_active Abandoned
- 2011-04-12 AU AU2011240620A patent/AU2011240620A1/en not_active Abandoned
- 2011-04-12 WO PCT/US2011/032188 patent/WO2011130328A1/en not_active Ceased
- 2011-04-12 EP EP11769477.8A patent/EP2560684A4/en not_active Withdrawn
- 2011-04-12 BR BR112012026003-0A patent/BR112012026003B1/pt active IP Right Grant
- 2011-04-12 SG SG2012070108A patent/SG184185A1/en unknown
- 2011-04-12 ES ES11769481T patent/ES2755398T3/es active Active
- 2011-04-12 JP JP2013505070A patent/JP6041799B2/ja active Active
- 2011-04-12 US US13/640,057 patent/US20130079280A1/en not_active Abandoned
- 2011-04-12 EP EP11769481.0A patent/EP2558495B1/en active Active
- 2011-04-12 CN CN2011800187879A patent/CN102834114A/zh active Pending
- 2011-04-12 CN CN201180018796.8A patent/CN102906112B/zh active Active
- 2011-04-12 WO PCT/US2011/032184 patent/WO2011130324A1/en not_active Ceased
- 2011-04-12 SG SG10201505470QA patent/SG10201505470QA/en unknown
- 2011-04-12 US US13/639,381 patent/US9212231B2/en active Active
- 2011-04-12 AU AU2011240624A patent/AU2011240624B2/en active Active
- 2011-04-12 RU RU2012147960A patent/RU2628699C2/ru active
- 2011-04-12 KR KR1020127029323A patent/KR101747991B1/ko active Active
- 2011-04-12 JP JP2013505069A patent/JP2013523179A/ja active Pending
- 2011-04-12 MX MX2012011840A patent/MX341119B/es active IP Right Grant
- 2011-04-12 KR KR1020127029343A patent/KR20130056870A/ko not_active Withdrawn
- 2011-04-12 CA CA2796010A patent/CA2796010C/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341119B (es) | Estructuras multiméricas específicas para ligando inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trail). | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| PE20181066A1 (es) | Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
| CY1121580T1 (el) | ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
| PE20150960A1 (es) | Inmunoglobulinas heterodimericas | |
| MX383471B (es) | Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. | |
| BR112015010360A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que pode se ligar especificamente ao sítio ii de uma il-6 humana, seus usos, ácido nucleico, composição, vetor, célula, e processo para produzir a mesma | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| BR112013026828A2 (pt) | polipeptídeos de anticorpo que antagonizam cd40 | |
| EA201591106A1 (ru) | Цеолитовые адсорбенты, способ их изготовления и их применение | |
| CO6400232A2 (es) | Proteína de enlace al receptores cgrp humano | |
| MX377846B (es) | Módulos de lanzadera de barrera cerebral sanguínea monovalente. | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20190354A1 (es) | Moduladores del factor del complemento b | |
| BR112014012275A2 (pt) | purificação de proteína com a utilização de tampão bis-tris | |
| EA201792485A3 (ru) | Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты) | |
| EA201790953A1 (ru) | Изменение экспрессии гена в cart-клетках и их применения | |
| TN2012000560A1 (en) | Glucagon analogues | |
| MX2017006695A (es) | Variantes de subtilasa y polinucleotidos que las codifican. | |
| BR112014013138A2 (pt) | anilinas substituídas como antagonistas de ccr(4) | |
| CL2011000769A1 (es) | Anticuerpo biespecifico que se une especificamente al factor de crecimiento endotelial vascular humano (vegf) y a la angiopoyetina-2 humana (ang-2); acido nucleico que lo codifica; vector de expresion recombinante; celula hospedadora; metodo de produccion del anticuerpo; composicion farmaceutica que lo comprende; y su uso para tratar el cancer. | |
| MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |